Holen Sie sich die Stockscreener-App
4.0971
1.56%
-0.0729
Schlusskurs vom Vortag:
$4.17
Offen:
$4.14
24-Stunden-Volumen:
214.59K
Relative Volume:
0.10
Marktkapitalisierung:
$676.66M
Einnahmen:
$361.51M
Nettoeinkommen (Verlust:
$102.18M
KGV:
6.8582
EPS:
0.5974
Netto-Cashflow:
$112.21M
1W Leistung:
-6.92%
1M Leistung:
-4.98%
6M Leistung:
+12.47%
1J Leistung:
+269.82%
1-Tages-Spanne:
$4.08
$4.16
1-Wochen-Bereich:
$4.075
$4.48
52-Wochen-Spanne:
$1.05
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.095 | 689.05M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
18.30 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.81 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.155 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.48 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
496.69 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow - AD HOC NEWS
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Slips 2.6% as Shares Approach Key Support at $3.92Backspread Trade - vinanet.vn
Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha
Ironwood (IRWD) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Market Move: The Market Price Moves 1.16% Higher in Latest TradingEarnings Yield Analysis - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportRSI Oversold Picks - vinanet.vn
Jeffrey Silber Net Worth (2026) - GuruFocus
Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Ironwood Pharmaceuticals (IRWD) Q2 2026 Earnings: EPS Misses Estimates, Stock Climbs 5.64%Dividend Growth Analysis - vinanet.vn
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - Stock Titan
Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock - Stock Titan
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacer Advisors Inc. Makes New $3.98 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call High - GuruFocus
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo! Finance Canada
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo Finance
IRWD Looks 15.8% Undervalued on GF Value™ as Debt Reduction Effo - GuruFocus
Ironwood Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-08-06 - Seeking Alpha
Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings - GuruFocus
IRWD: LINZESS sales surged and guidance was raised as apraglutide advanced in phase III trials - TradingView
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates - Yahoo Finance
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Raises 2026 Guidance After Q2 Revenue Hits $113 Million - Quiver Quantitative
BRIEF-Ironwood Pharmaceuticals Q2 Revenue USD 113.041 Million Vs. IBES Estimate USD 114.8 Million - TradingView
Press Release: Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Moomoo
Segall Bryant & Hamill LLC Buys New Position in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Lazard Asset Management LLC Sells 710,256 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) Advances 2.89% to $4.27 — Key Resistance at $4.48 in FocusRevenue Growth Stocks - vinanet.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Ironwood Pharmaceuticals (IRWD) Surges 13% as Biotech Momentum BuildsLow Vol Factor - vinanet.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 8.7%Should You Buy? - MarketBeat
Ironwood Pharmaceuticals Q1 2026 Earnings: Slight EPS Miss Overshadowed by Positive Stock MomentumEPS Revision Trend - vinanet.vn
Ironwood Pharmaceuticals Inc (IRWD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood - Stock Titan
Ironwood Pharmaceuticals Inc (IRWD) Institutional Confidence - TradingKey
Return on assets % of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76 - TradingView
Total operating expenses of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76 - TradingView
Ironwood Pharmaceuticals Inc (IRWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AbbVie Seeks Block On Alkem Generic Constipation Drug - Law360
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – BX:I76 - TradingView
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:I76 - TradingView
Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):